Anebulo Pharmaceuticals, Inc. (ANEB) Research
Anebulo Pharmaceuticals, Inc. is a biotechnology firm currently in the clinical trial phase, committed to devising and introducing treatments for individuals affected by severe cannabinoid poisoning and various forms of substance dependency. Its leading experimental drug, ANEB-001, is a small molecule engineered to counteract cannabinoid receptors, specifically targeting both cannabinoid intoxication and overdose. The company was founded in 2020 and maintains its headquarters in Lakeway, Texas.
Market snapshot
- Symbol
- ANEB
- Price
- $0.39
- Day change
- -15.22%
- Market cap
- $15.9M
- P/E ratio
- -2.01x
- 52-week range
- 0.3-3.42
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 3 months
- Analyst price target
- $6.00
Peer companies
Recent insider activity
- Lawler Joseph F. — A-Award (25000 shares) on 2025-04-04
- Lawler Joseph F. — A-Award (13236 shares) on 2025-04-04
- SHAH BIMAL R. — A-Award (25000 shares) on 2025-04-04
- SHAH BIMAL R. — A-Award (6618 shares) on 2025-04-04
- Cundy Kenneth C — A-Award (115037 shares) on 2025-04-04
Open Anebulo Pharmaceuticals, Inc. (ANEB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.